Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: A systematic review and meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 16, 2013, Pages 1393-1401

  Tricco, Andrea C ^a   Soobiah, Charlene ^a   Berliner, Shirra ^a   Ho, Joanne M ^a   Ng, Carmen H ^a   Ashoor, Huda M ^a   Chen, Maggie H ^a   Hemmelgarn, Brenda ^b   Straus, Sharon E ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; MORTALITY; NAUSEA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VOMITING;

EID: 84887267473     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.130451     Document Type: Article

References (44)

1. Chertkow H. diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the diagnosis and Treatment of dementia. CMAJ 2008;178:316-21.
2. Ward A, Arrighi HM, Michels S, et al. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement 2012;8:14-21.
3. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a delphi consensus study. Lancet 2005;366:2112-7.
4. Farias ST, Mungas d, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009;66:1151-7.
5. Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry 2006;189:399-404.
6. Landau SM, Harvey d, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-8.
7. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues Clin Neurosci 2004;6:401-8.
8. dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Leicester (UK): British Psychological Society and London (ON): The Royal College of Psychiatrists; 2007.
9. Perras C, Shukla VK, Lessard C, et al. Cholinesterase inhibitors for Alzheimer's disease: a systematic review of randomized controlled trials [Technology report no. 58]. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment; 2005.
10. Pedone C, Lapane KL, Mor V, et al. donepezil use in US nursing homes. Aging Clin Exp Res 2004;16:60-7.
11. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; 9: Cd009132.
12. Moher d, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
13. Moher d, Shamseer L, Clarke M, et al. Reporting guidelines for systematic review protocols. Proceedings of the 19th Cochrane Colloquium; 2011 Oct. 19-22; Madrid (Spain).
14. Tricco AC, Soobiah C, Lillie E, et al. Use of cognitive enhancers for mild cognitive impairment: protocol for a systematic review and network meta-analysis. Syst Rev 2012;1:25.
15. Sampson M, McGowan J, Cogo E, et al. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 2009;62:944-52.
16. Soobiah C, Straus SE, Blondal E, et al. Outcomes utilized to assess Alzheimer's disease from a systematic review and survey of decision- makers. Proceedings from the Canadian Geriatrics Society 33rd Annual Scientific Meeting; 2012 Apr. 18-20 Toronto (ON).
17. Rosen WG, Mohs RC, davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
19. Galasko d, Bennett d, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-9.
20. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
21. Knopman dS, Knapp MJ, Gracon SI, et al. The Clinician Interview- Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-21.
22. Higgins JP, Altman dG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
23. Santaguida P, Raina P. The development of the McHarm Quality Assessment Scale for adverse events. 2008. Available: http://hiru.mcmaster.ca/epc/mcharm. pdf (accessed 2013 Sep. 3).
24. derSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002;21:1539-58.
26. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589-624.
27. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35.
28. Özenli Y, Yagci d, Karaca S. Efficacy of donepezil on cognitive functions in mild cognitive impairment. Klinik Psikofarmakoloji Bulteni 2007;17:62-7.
29. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004;63:651-7.
30. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88.
31. doody RS, Ferris SH, Salloway S, et al. donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72:1555-61.
32. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InddEx study. Lancet Neurol 2007;6:501-12.
33. Ferris S, Schneider L, Farmer M, et al. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry 2007; 22: 448-55.
34. Ferris S, Nordberg A, Soininen H, et al. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyryl cholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics 2009;19:635-46.
35. Lu PH, Edland Sd, Teng E, et al. donepezil delays progression to Ad in MCI subjects with depressive symptoms. Neurology 2009; 72:2115-21.
36. Schneider LS, Raman R, Schmitt FA, et al. Characteristics and performance of a modified version of the AdCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Dis Assoc Disord 2009;23:260-7.
37. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Hoboken (NJ): John Wiley & Sons; 2009.
38. Birks J, Flicker L. donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006; (3):Cd006104.
39. Peters O, Lorenz d, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012;16:544-8.
40. Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand 2010;121:217-24.
41. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebocontrolled study. Am J Alzheimers Dis Other Demen 2005;20:295-302.
42. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21:2313-24.
43. Schulz KF, Altman dG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7: e1000251.
44. Egger M, davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.